These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 23726889)
21. What's next after 50 years of psychiatric drug development: an FDA perspective. Laughren TP J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624 [TBL] [Abstract][Full Text] [Related]
22. The odyssey of marine pharmaceuticals: a current pipeline perspective. Mayer AM; Glaser KB; Cuevas C; Jacobs RS; Kem W; Little RD; McIntosh JM; Newman DJ; Potts BC; Shuster DE Trends Pharmacol Sci; 2010 Jun; 31(6):255-65. PubMed ID: 20363514 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864 [TBL] [Abstract][Full Text] [Related]
26. Trends in risks associated with new drug development: success rates for investigational drugs. DiMasi JA; Feldman L; Seckler A; Wilson A Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567 [TBL] [Abstract][Full Text] [Related]
27. Peptide therapeutics from venom: Current status and potential. Pennington MW; Czerwinski A; Norton RS Bioorg Med Chem; 2018 Jun; 26(10):2738-2758. PubMed ID: 28988749 [TBL] [Abstract][Full Text] [Related]
28. [Current state and vision of the development of new antipsychotic drugs]. Takekita Y; Kinoshita T Nihon Rinsho; 2013 Apr; 71(4):730-6. PubMed ID: 23678608 [TBL] [Abstract][Full Text] [Related]
29. Peptide therapeutics: current status and future directions. Fosgerau K; Hoffmann T Drug Discov Today; 2015 Jan; 20(1):122-8. PubMed ID: 25450771 [TBL] [Abstract][Full Text] [Related]
30. [New drug approvals over three decades from 1980 to 2009 in Japan--their therapeutic targets and biochemical properties]. Muramatsu M; Arisue Y Yakugaku Zasshi; 2011 Apr; 131(4):603-19. PubMed ID: 21467801 [TBL] [Abstract][Full Text] [Related]
31. Industry and regulatory performance in 2012: a year in review. Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160 [TBL] [Abstract][Full Text] [Related]
33. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan. Kawabata-Shoda E; Masuda S; Kimura H J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857 [TBL] [Abstract][Full Text] [Related]
34. Re-engineering drug discovery and development. FitzGerald GA LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582 [TBL] [Abstract][Full Text] [Related]
35. [Targeted therapies in severe asthma: the discovery of new molecules]. Charriot J; Gamez AS; Humbert M; Chanez P; Bourdin A Rev Mal Respir; 2013 Oct; 30(8):613-26. PubMed ID: 24182649 [TBL] [Abstract][Full Text] [Related]
36. Protein and Peptide Biopharmaceuticals: An Overview. Agyei D; Ahmed I; Akram Z; Iqbal HM; Danquah MK Protein Pept Lett; 2017; 24(2):94-101. PubMed ID: 28017145 [TBL] [Abstract][Full Text] [Related]
37. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Nagle PC; Nicita CA; Gerdes LA; Schmeichel CJ Am J Manag Care; 2008 Apr; 14(4):226-9. PubMed ID: 18402515 [TBL] [Abstract][Full Text] [Related]
39. Building on Success: A Bright Future for Peptide Therapeutics. Angell Y; Holford M; Moos WH Protein Pept Lett; 2018; 25(12):1044-1050. PubMed ID: 30430932 [TBL] [Abstract][Full Text] [Related]
40. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Espinel-Ingroff A Rev Iberoam Micol; 2009 Mar; 26(1):15-22. PubMed ID: 19463273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]